You should consult the privacy policies of any third party that provides content that you access through the Services as we do not control and are not responsible for the information that they collect, use, or share
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
Non-Diabetes Specialists Drive New Growth in GLP-1 Prescriptions Patients with Type 2 diabetes (T2D) and obesity often present with multiple comorbidities spanning a wide range of diseases, requiring care from diverse specialists
Despite identical food intake and fasting at endpoint, while WM-CR did not alter cecal content mass compared to Veh controls, incretin agonism significantly elevated cecal content weight at endpoint
Nausea is the dominant adverse event across all three compounds, but incidence and severity track titration speed more than receptor count
Monitoring suicidal patients in primary care using electronic health records
